
    
      Approximately 330 eligible subjects will be randomly allocated to one of the following 2
      treatment arms in a 1:1 ratio:

      Investigational Arm:

      Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day
      cycle).

      Control Arm:

      Recommended doses and schedules as per NCCN guidelines (with dose modifications if too
      toxic).

      Eribulin; Capecitabine; Gemcitabine; Vinorelbine Subjects will be treated until PD as judged
      by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
    
  